Available pharmaceutical product listings identify Glenmark Pharmaceuticals Ltd. as the manufacturer/marketer of Abirapro 250 mg.
Glenmark and Abirapro
Abirapro 250 mg is listed as an abiraterone acetate product manufactured/marketed by Glenmark Pharmaceuticals Ltd. The exact authorization holder and manufacturing site can vary by jurisdiction and should be confirmed from local regulatory documentation.
Glenmark versus the originator
Glenmark should not be confused with the original developer of abiraterone.
The scientific origins of abiraterone trace to the Institute of Cancer Research. The compound was subsequently licensed to Cougar Biotechnology, which developed the commercial medicine; Cougar was acquired by Johnson & Johnson.
The reference product Zytiga was developed through this commercial pathway, while Abirapro is a separate product.
Manufacturer terminology
A pharmaceutical website should distinguish:
- Original developer
- Reference-product company
- Specific manufacturer
- Brand owner
- Marketing authorization holder
- Distributor
- Supplier
These roles are not automatically held by the same company.
Product-specific regulatory information
The exact marketing authorization holder for Abirapro in each country is [Information requires verification].
Quality information
Specific manufacturing-site certifications, GMP certificates and batch-release arrangements should be verified from official company or regulatory documents rather than assumed.